Celgene (CELG) – Research Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Celgene (NASDAQ: CELG) in the last few weeks:

  • 2/4/2018 – Celgene had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $128.00 price target on the stock.
  • 1/31/2018 – Celgene was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Celgene’s fourth-quarter results were encouraging as the company beat on both sales and earnings. While Revlimid sales were impressive yet again, Abraxane sales declined in the United States. Sales of Otezla have picked up too after a slowdown in the third quarter. However, Celgene is highly dependent on Revlimid. Celgene’s stock has underperformed the industry in the last six months. Celgene suffered a setback as the label expansion study on lead drug Revlimid failed in phase III. The stock was hit earlier after a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn’s disease and the extension trial, SUSTAIN (CD-004) was discontinued.  The threat of generic competition is also looming large on Revlimid forcing Celgene to look for acquisitions and the announcement of Juno’s acquisition was on the same track. However, the Juno acquisition comes with its own set of risks.”
  • 1/29/2018 – Celgene had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $112.00 price target on the stock. They wrote, “CELG’s current CEO, Mark Alles, will assume the role of Chairman of the Board, following the retirement of current COB Robert Hugin, effective February 5th, which follows his departure as President in early 2016.””
  • 1/26/2018 – Celgene had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $139.00 price target on the stock, up previously from $127.00.
  • 1/25/2018 – Celgene was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $116.84 price target on the stock.
  • 1/24/2018 – Celgene had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $144.00 price target on the stock.
  • 1/23/2018 – Celgene had its “top pick” rating reaffirmed by analysts at Royal Bank of Canada.
  • 1/23/2018 – Celgene had its “hold” rating reaffirmed by analysts at BTIG Research.
  • 1/23/2018 – Celgene was given a new $112.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock. They wrote, “4Q17 non-GAAP EPS of $2.00 was ahead of our $1.95 forecast and FactSet consensus of $1.97, on revenue of $3.48 bln, which was slightly below our forecast of $3.58 bln.””
  • 1/20/2018 – Celgene was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/18/2018 – Celgene had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $104.00 price target on the stock.
  • 1/17/2018 – Celgene was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $114.80 price target on the stock.
  • 1/17/2018 – Celgene was given a new $112.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock. They wrote, “The Wall Street Journal (WSJ) has reported that CELG is in talks to buy JUNO (NC), or rather the 90% of the company that CELG does not already own.””
  • 1/17/2018 – Celgene was given a new $128.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 1/10/2018 – Celgene had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $147.00 price target on the stock.
  • 1/8/2018 – Celgene was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Celgene’s Revlimid continue to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration. Pomalyst and Abraxane also performed well. The approval of Idhifa for relapsed and/or refractory acute myeloid leukemia has further boosted the company’s portfolio. However, Celgene is highly dependent on Revlimid. Celgene suffered a setback as the label expansion study on lead drug Revlimid failed in phase III. The drug’s label expansion would have boosted its sales potential. Additionally, the deep yet persistently slow growth of the psoriatic arthritis and psoriasis markets, especially during the entire third quarter, has led to a weak performance of Otezla. Consequently, the company also reduced its annual guidance. Shares have underperformed the industry in the last six months. “
  • 1/8/2018 – Celgene was given a new $127.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “buy” rating on the stock.
  • 1/8/2018 – Celgene was given a new $125.00 price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 1/8/2018 – Celgene was given a new $130.00 price target on by analysts at Stifel Nicolaus. They now have a “buy” rating on the stock.
  • 1/8/2018 – Celgene was given a new $110.00 price target on by analysts at Deutsche Bank AG. They now have a “hold” rating on the stock.
  • 1/8/2018 – Celgene was given a new $166.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 1/8/2018 – Celgene was given a new $112.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 1/5/2018 – Celgene was given a new $128.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 1/5/2018 – Celgene was downgraded by analysts at Bank of America Corp from a “buy” rating to a “neutral” rating. They now have a $120.00 price target on the stock, up previously from $104.68.
  • 1/4/2018 – Celgene had its “buy” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $147.00 price target on the stock.
  • 12/31/2017 – Celgene was given a new $127.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “buy” rating on the stock.
  • 12/30/2017 – Celgene had its price target lowered by analysts at Stifel Nicolaus from $149.00 to $130.00. They now have a “buy” rating on the stock.
  • 12/29/2017 – Celgene was given a new $112.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock. They wrote, “CELG will record a pretax charge of approximately $411 million in 4Q17 in relation to the wind-down of the GED-0301 program, announced in October 2017.””
  • 12/28/2017 – Celgene was given a new $166.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 12/28/2017 – Celgene was given a new $123.00 price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 12/27/2017 – Celgene was downgraded by analysts at Sanford C. Bernstein from an “outperform” rating to a “market perform” rating. They now have a $121.00 price target on the stock.
  • 12/26/2017 – Celgene was given a new $128.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 12/26/2017 – Celgene was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Celgene suffered a setback as the label expansion study on lead drug Revlimid failed in phase III. Revlimid plus Rituxan failed to show superiority in the co-primary endpoints of complete response or unconfirmed complete response CR/CRu) at 120 weeks and in terms of progression-free survival observed during the pre-planned analysis.The drug’s label expansion would have boosted its sales potential. Additionally, the deep yet persistently slow growth of the psoriatic arthritis and psoriasis markets, especially during the entire third quarter, has led to a weak performance of Otezla. Consequently, the company also reduced its annual guidance. The challenging market conditions were driven by an increasingly restrictive PBM formulary control. Nevertheless, the approval of Idhifa for relapsed and/or refractory acute myeloid leukemia has boosted the company’s portfolio. Shares have underperformed the industry in the last six months.”
  • 12/25/2017 – Celgene was given a new $152.00 price target on by analysts at Guggenheim. They now have a “buy” rating on the stock.
  • 12/25/2017 – Celgene was given a new $127.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “buy” rating on the stock.
  • 12/22/2017 – Celgene had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $120.00 price target on the stock.
  • 12/22/2017 – Celgene had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $147.00 price target on the stock.
  • 12/22/2017 – Celgene had its “hold” rating reaffirmed by analysts at Citigroup Inc.
  • 12/22/2017 – Celgene was given a new $166.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 12/22/2017 – Celgene was given a new $123.00 price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 12/22/2017 – Celgene had its price target lowered by analysts at Stifel Nicolaus from $149.00 to $130.00. They now have a “buy” rating on the stock.
  • 12/21/2017 – Celgene was given a new $112.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 12/18/2017 – Celgene was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $121.72 price target on the stock.
  • 12/14/2017 – Celgene was given a new $166.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.

Shares of Celgene Co. (NASDAQ:CELG) opened at $92.51 on Monday. Celgene Co. has a one year low of $88.32 and a one year high of $147.17. The company has a quick ratio of 4.80, a current ratio of 4.99 and a debt-to-equity ratio of 2.29. The company has a market capitalization of $69,583.77, a PE ratio of 25.84, a PEG ratio of 0.66 and a beta of 1.49.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. During the same quarter in the prior year, the business earned $1.61 earnings per share. The company’s revenue was up 16.9% compared to the same quarter last year. research analysts expect that Celgene Co. will post 7.68 EPS for the current fiscal year.

In other Celgene news, insider Mark J. Alles purchased 3,260 shares of Celgene stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average price of $91.90 per share, with a total value of $299,594.00. Following the acquisition, the insider now owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.95% of the company’s stock.

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Receive News & Ratings for Celgene Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply